Randomized controlled trial assesses pain relief and bleeding reduction in fissure treatment, suggesting Parnabeejadi may outperform diclofenac.
Acute fissure-in-ano is a distressing and common anorectal condition characterized by painful defecation and rectal bleeding. Although several treatment modalities are available in conventional surgery, the search for an effective and safe remedy remains ongoing. This study aims to assess the efficacy of Parnabeejadi rectal suppository as compared to diclofenac rectal suppository in managing acute fissure-in-ano. It was an open-label randomized controlled clinical trial. A total of 30 patients were enrolled in each group, patients of Group A received Parnabeejadi rectal suppository whereas patients of Group B were treated with diclofenac rectal suppository per anum, twice a day for a period of 2 weeks. The parameters for assessment were pain in the anal region, measured using a Visual Analog Scale, burning sensation, and bleeding P/R. Both groups showed a highly significant reduction in pain and burning sensation after 2 weeks of treatment, whereas the Parnabeejadi group had a better effect on bleeding P/R compared to the diclofenac group (P < 0.05).
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: